For the year ending 2025-12-31, RKDA made $4,858K in revenue. -$2,339K in net income. Net profit margin of -48.15%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 4,858 | 5,045 | ||
| Cost of revenues | 3,098 | 2,963 | ||
| Research and development | 9 | 53 | ||
| Gain on sale of intangible assets | 750 | 4,000 | ||
| Impairment of property and equipment | 0 | 36 | ||
| Change in fair value of contingent consideration | 2,000 | - | ||
| Selling, general and administrative | 7,001 | 9,641 | ||
| Total operating expenses | 7,358 | 8,693 | ||
| Loss from operations | -2,500 | -3,648 | ||
| Interest income | 221 | 782 | ||
| Credit loss | -4,745 | - | ||
| Other income, net | 2,309 | 31 | ||
| Change in fair value of common stock warrant and option liabilities | 2,384 | -1,474 | ||
| Net loss from continuing operations before income taxes | -2,331 | -4,309 | ||
| Income tax expense | 8 | 8 | ||
| Net loss from continuing operations | -2,339 | -4,317 | ||
| Net loss from discontinued operations | - | -2,721 | ||
| Net loss | - | -7,038 | ||
| Net loss from discontinued operations | 0 | - | ||
| Net loss attributable to common stockholders | -2,339 | -7,038 | ||
| Basic EPS | -1.71 | -5.17 | ||
| Diluted EPS | -1.71 | -5.17 | ||
| Basic Average Shares | 1,368,057 | 1,363,303 | ||
| Diluted Average Shares | 1,368,057 | 1,363,303 | ||
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)